Altre lingue BioInvent International AB

Azioni

BINV

SE0015244520

Tempo reale stimato Cboe Europe Altri mercati azionari 09:31:31 18/04/2024			Variaz. 5gg	Var. 1 gen.
22,18 ^SEK	+3,14%		+19,44%	+16,03%

03/04	BioInvent, l'unità Merck & Co. Co. firma un accordo di sperimentazione clinica e fornitura per il trattamento del tumore come terapia aggiuntiva a Keytruda.	MT
22/02	Transcript : BioInvent International AB, 2023 Earnings Call, Feb 22, 2024

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

BioInvent International AB publishes Annual Report 2023	04/04
BioStock: BioInvent deepens collaboration with MSD	04/04
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company s second anti-TNFR2 antibody in combination with KEYTRUDA	03/04
BioInvent, Merck & Co. Unit Sign Clinical Trial, Supply Deal for Tumor Treatment as Add-On Therapy for Keytruda	03/04
BioInvent International : announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)	02/04
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company’s second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)	02/04
Notice to Annual General Meeting in BioInvent International AB	27/03
BioStock: BioInvent's CEO comments on the study success in China	11/03
BioInvent International, CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed, Refractory Indolent Non-Hodgkin's Lymphoma In China	06/03
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China	05/03
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma In China	05/03
BioInvent International AB Year-end report January 1, December 31, 2023	23/02
BioInvent Q4 2023 - Now a mid-stage clinical company	23/02
BioInvent International AB Year-end report January 1 – December 31, 2023	22/02
BioInvent International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
BioInvent International AB Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Invitation to presentation of BioInvent's Year-end report 2023	21/02
Invitation to presentation of BioInvent’s Year-end report 2023	20/02
BioInvent to evaluate BI-1206 in combination with rituximab and Calquence	09/02
BioStock: BioInvent expects data from seven clinical studies in 2024	18/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue BioInvent International AB

Azioni

BINV

SE0015244520

Altre lingue

Filtri